• EDC.HCl (3-(ethyliminomethylideneamino)-N,N-dimethylpropan-1

  2026-05-29

  EDC.HCl (3-(ethyliminomethylideneamino)-N,N-dimethylpropan-1-amine hydrochloride) enables efficient amide bond formation during peptide synthesis, bioconjugation, and nucleotide coupling reactions in aqueous environments. It is strictly intended for in vitro laboratory workflows, as there is no evidence supporting in vivo or clinical use.

• Targeting SPP1 in Tumor Macrophages: Small Molecule Strategi

  2026-05-28

  This article analyzes a recent study that identifies and validates small molecule inhibitors of SPP1 in tumor-associated macrophages (TAM), demonstrating potent in vitro and in vivo tumor suppression. The findings provide a mechanistic framework for developing TAM-targeted therapies and inform future research on immunosuppressive tumor microenvironments.

• DMXAA (Vadimezan): Reimagining Tumor Vasculature Disruption

  2026-05-28

  This thought-leadership article explores DMXAA (Vadimezan) as a next-generation vascular disrupting agent, focusing on its mechanistic roles in endothelial apoptosis, angiogenesis inhibition, and STING-JAK1 immune modulation. With new insights bridging tumor microenvironment normalization and translational strategies, the article provides actionable guidance for researchers aiming to leverage DMXAA in advanced cancer biology research, particularly in non-small cell lung cancer (NSCLC) models.

• Cy5 NHS ester(Et): Practical Guide for Protein Fluorescent L

  2026-05-27

  Cy5 NHS ester(Et) provides a water-soluble solution for covalent fluorescent labeling of primary amines in proteins and other biomolecules, supporting applications such as immunofluorescence, flow cytometry, and fluorescence microscopy. It is unsuitable for ethanol-based protocols or for workflows requiring long-term storage of working solutions, and is best applied in immediate-use labeling procedures.

• Crizotinib Hydrochloride: Benchmarking ALK Inhibition in Nex

  2026-05-27

  Explore the use of Crizotinib hydrochloride as a gold-standard ALK kinase inhibitor in advanced cancer research. Discover how integration with patient-derived assembloid models deepens mechanistic insight and refines drug screening strategies.

• Viral Modulation of RIPK3: Proteasome-Mediated Control of In

  2026-05-26

  Liu et al. identified a family of orthopoxvirus proteins (vIRD) that bind the SCF ubiquitin ligase complex and induce proteasomal degradation of RIPK3, thereby inhibiting necroptosis and modulating virus-induced inflammation. This discovery clarifies a pivotal mechanism by which viruses regulate host cell death pathways and immune responses, with broad implications for understanding viral pathogenesis and therapeutic targeting.

• CB-5083: Advanced Strategies for Targeting Protein Homeostas

  2026-05-26

  Explore how CB-5083, a selective p97 inhibitor, empowers innovative approaches to disrupt protein homeostasis in cancer research. This article uniquely bridges mechanistic insights with assay design, featuring recent advances in ER regulation.

• Phytol: Unveiling RXR Activation and Lyotropic Design Insigh

  2026-05-25

  Explore how Phytol unlocks advanced retinoid X receptor signaling and PPARα regulation, with a unique focus on lyotropic phase behavior. This in-depth analysis provides fresh perspectives for researchers seeking to bridge molecular mechanisms with nanomaterial innovation.

• MG-132 (Z-LLL-al): Mechanisms, Evidence, and Workflow Use

  2026-05-25

  MG-132 (Z-LLL-al) is a potent, cell-permeable proteasome inhibitor widely used in apoptosis and cell cycle arrest studies. Its selective inhibition and robust performance in cancer research have made it a benchmark tool for dissecting ubiquitin-proteasome system functions.

• Dual-Action Inhibition of p38α MAPK: Mechanistic Insights an

  2026-05-24

  This study reveals how certain kinase inhibitors not only block p38α MAPK activity but also accelerate its dephosphorylation by stabilizing a phosphatase-accessible conformation. The findings provide a new framework for designing more potent and specific p38 MAPK inhibitors, with direct implications for inflammation and cytokine signaling research.

• Notch Inhibition Boosts Immunotherapy in Triple-Negative Bre

  2026-05-23

  This study demonstrates that targeting the Notch signaling pathway can remodel the tumor immune microenvironment and dramatically enhance immune checkpoint blockade efficacy in triple-negative breast cancer (TNBC). The findings highlight a mechanistic link between Notch-driven cytokine signaling, macrophage recruitment, and tumor immune escape, providing a compelling rationale for combining Notch inhibition with immunotherapy in aggressive breast cancers.

• E-64d: Precision Cysteine Protease Inhibition in Lysoptosis

  2026-05-22

  Discover how E-64d, a potent membrane-permeable cysteine protease inhibitor, redefines assay precision in lysoptosis and apoptosis studies. This article uniquely explores the compound’s mechanistic selectivity and practical integration in advanced experimental models.

• 10058-F4 C-Myc-Max Dimerization Inhibitor: Applied Workflows

  2026-05-22

  10058-F4 offers targeted disruption of c-Myc-Max dimerization, providing a robust tool for probing oncogenic transcription and apoptosis in leukemia and prostate cancer research. This guide delivers optimized protocols, troubleshooting strategies, and data-driven insights for maximizing reproducibility and impact in advanced cell-based assays.

• Alda 1 and ALDH2 Activation: Catalyzing New Frontiers in Car

  2026-05-21

  Emerging evidence positions Alda 1, a potent ALDH2 activator, as a pivotal tool for translational researchers targeting cardioprotection and tissue regeneration. This article integrates mechanistic insights with strategic guidance, highlighting Alda 1’s unique capacity to enhance cardiomyocyte proliferation, mitigate radiation-induced dermatitis, and bridge critical research gaps in aldehyde detoxification. Drawing on recent breakthroughs and APExBIO’s product innovation, we explore actionable strategies to advance cardiac ischemia research and beyond.

• Sildenafil Citrate in Proteoform-Specific Vascular Research

  2026-05-21

  Explore how Sildenafil Citrate, a potent cGMP-specific phosphodiesterase type 5 inhibitor, is revolutionizing proteoform-specific vascular research. This article goes beyond conventional applications, offering a practical guide to leveraging proteomics insights for advanced assay design.

414 records 14/28 page Previous Next First page 上5页 1112131415 下5页 Last page